ReviewDiagnostics (Basel, Switzerland)2023
Drug-Resistant
Review in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Levofloxacin versus moxifloxacin in nitazoxanide-based quadruple therapy as a first-line treatment for Helicobacter pylori infection: NILE, a randomized, comparative, multicenter study.Scientific reports · 2026Trial
- Clinical validation of a fecal PCR assay forJournal of clinical microbiology · 2026Observational
- Double-site rapid urease test versus histopathology for the diagnosis of Helicobacter pylori among patients with dyspepsia on proton pump inhibitors-A diagnostic accuracy study.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Article
- Transcriptomic and Molecular Insights into the Response of Multidrug-Resistant Helicobacter pylori to Human Neutrophil Peptide 1 (HNP-1).Probiotics and antimicrobial proteins · 2026Article
- Comparison of Next-Generation Sequencing, Real-Time PCR and HRM-PCR forMicroorganisms · 2025Article
- Diagnosis and treatment ofFuture microbiology · 2025Review
- Anti-urease therapy: a targeted approach to mitigating antibiotic resistance in Helicobacter pylori while preserving the gut microflora.Gut pathogens · 2025Review
- Multidisciplinary Approach Improves Eradication Rate and Safety in Refractory Helicobacter pylori Infection.Clinical and translational gastroenterology · 2025Article
- Repurposing FDA-Approved Agents to Develop a PrototypePharmaceuticals (Basel, Switzerland) · 2025Article
- Genomic insights into antibiotic resistance, virulence traits and phylogenetic lineages of 141 clinicalFrontiers in cellular and infection microbiology · 2025Article
- Change in Diagnosis ofAntibiotics (Basel, Switzerland) · 2024Review
- Concomitant and Bismuth Quadruple Therapy forAntibiotics (Basel, Switzerland) · 2024Article
- Antibiotic Resistance and Therapy forAntibiotics (Basel, Switzerland) · 2023Article
- Antibiotic Resistance inAntibiotics (Basel, Switzerland) · 2023Article
- Prevalence and Risk Factors Associated withActa gastroenterologica LatinoamericanaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.